Clinical Trial Update: Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update evaluating erlotinib hydrochloride as adjuvant therapy after complete surgical resection for stage IB-IIIA non-small cell lung c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lung Non-Squamous Non-Small Cell Carcinoma, Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Phase 3 | Status: ACTIVE_NOT_RECRUITING